| Name | Title | Contact Details |
|---|---|---|
Adam Carreno |
Chief Executive Officer and Technology Advisor | Profile |
Medical Claims Processing and Payer Solutions are Imagenets core business. Through our Paper to EDI, Adjudication, Claims Audit, and Contact Center solutions, Imagenet partners with each of our clients to ensure their compliance and business continuity needs are met, while helping implement bottom line efficiencies. All our solutions are Client Managed solutions, meaning your organization only supplies the business rules, and we respond with the tools, infrastructure, personnel, and subject matter experts, to accomplish the goals that your organization set out to accomplish. Our success is built upon our collaborative approach to engaging and delivering solutions to our trusted client partners. From our growing list of regional and locally staffed facilities, Imagenet performs as a natural extension of our client partners by delivering our solutions from local operating centers. Regional Facilities Located In: Arizona | California | Florida | Idaho | New Jersey | Pennsylvania | Texas | Washington
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
We partner with low-income and working people to build economic and racial equity. We do this by confronting economic abuse and investing in community wealth. We use an ever-evolving set of legal, economic and advocacy tools to challenge and dismantle unjust systems, building quickly towards a world where all people have what they need to live and thrive.
CI Financial is an independent company offering global asset management and wealth management advisory services. We are driven by a commitment to provide individuals and institutions with the highest-quality investments and advice—and offer a comprehensive and innovative selection of strategies and services. Our employees are at the heart of everything we do. They must be comfortable in a fast-paced environment in an industry that is always changing. A healthy dose of ambition, a willingness to go the extra mile and a strong sense of camaraderie are what we look for in our team members.